Xconomy: Resolve Maps Out New Biotech Model, SeaGen Expands, Schadt Heads East, & More in Seattle-Area Life Sciences News
Summary
I’m going to put this question up for a debate between Sage co-founder Stephen Friend and MIT’s legendary biologist, Phil Sharp, at Xconomy’s biggest event of the year, XSITE, in suburban Boston on June 16.A few other familiar faces to readers in Seattle—Charlotte Hubbert of Accelerator, Norm Wu of Qliance Medical Management, and Mike Martino of Carefusion—will also be part of the agenda at the XSITE conference.—First things first, I’m running another event for Xconomy here tonight in Seattle called “Separating Hype from Reality in Alternative Fuels.” Yesterday, I laid out the program highlights, which include big ideas being backed by Boeing, Bill Gates, Waste Management, and Kleiner Perkins Caufield & Byers, among others.Instead of relying on a future IPO or acquisition, Resolve is seeking to generate returns through striking a licensing deal in a few years with a Big Pharma company.—Bothell, WA-based Marina Biotech (NASDAQ: MRNA), the RNA interference company that’s like a cat with nine lives, raised another $6.9 million through a stock offering this week.